Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.70 |
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25C | P30307 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517191 | 0.94 | AURKA (0.70) | AURKAAURKBPARP1DAOUTS2R | |
| SCHEMBL6521696 | 0.85 | AURKA (0.67) | AURKAAURKBPARP1DAOCDC25A | |
| SCHEMBL6521579 | 0.85 | AURKA (0.67) | AURKAAURKBPARP1DAOERBB2 | |
| SCHEMBL679019 | 0.83 | AURKA (1.00) | AURKAAURKBPARP1DAOERBB2 | |
| SCHEMBL6523418 | 0.79 | AURKA (0.67) | AURKAAURKBPARP1DAOPTK6 | |
| SCHEMBL6518381 | 0.79 | AURKA (0.58) | AURKAAURKBPARP1DAOALDH1A1 | |
| SCHEMBL6527216 | 0.78 | AURKA (0.61) | AURKAAURKBDAOPTK6ALDH1A1 | |
| SCHEMBL3454682 | 0.77 | AURKA (0.63) | AURKAAURKBPARP1DAOPTK6 | |
| SCHEMBL3454039 | 0.77 | PARP1 (0.68) | AURKAAURKBPARP1DAOALDH1A1 | |
| SCHEMBL14237126 | 0.76 | PARP1 (0.62) | AURKAAURKBPARP1DAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | AURKA 538/4885AURKB 487/4885PARP1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.